Statement: Federal Cost of a National Pharmacare Program

Posted on September 28, 2017

Ottawa, September 28, 2017

The following statement can be attributed to Innovative Medicines Canada’s president, Pamela Fralick:

“Innovative Medicines Canada and its member companies are proud to be an integral part of our country’s healthcare system, and will support any program that put patients first while ensuring they have fair, equitable and affordable access to the medicines they need, when they need them.

“The Parliamentary Budget Officer Report notes that access to prescription medicines across the country remains inconsistent and inequitable. We believe that we can do better for Canadian patients.

“Innovative Medicines Canada believes in closing the gaps in coverage to help those who are uninsured and underinsured, while maintaining the option for those with comprehensive drug coverage. Any solution needs to ensure that no one is worse off or has fewer options. We should also ensure the health system achieves best outcomes by providing access to a full range of medicines to meet each patient’s unique needs.

“As the public policy discussion on national pharmacare continues, we are strongly committed to working collaboratively with governments and other healthcare stakeholders to develop sustainable solutions to ensure more timely and consistent patient access to medicines.”

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

-30-

For further information:

Sarah Dion-Marquis
Director, Media and Public Relations
Telephone: 613-769-6510
sdmarquis@imc-mnc.ca

Leave a Reply

Your email address will not be published. Required fields are marked *